Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.

DD, Ruff; JH, Ford; A, Tockhorn-Heidenreich; VL, Stauffer; S, Govindan; SK, Aurora; GM, Terwindt; PJ, Goadsby

doi:10.1111/ene.14114

Public

Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.

Shared by NobleBlocks on Dec 2, 2019 • 12:00 AM UTC

Authors:

Ruff DD

Ford JH

Tockhorn-Heidenreich A

Abstract

<h4>Background and purpose</h4>The efficacy of galcanezumab, a monoclonal antibody for migraine prevention, has been demonstrated in two pivotal trials in patients with episodic migraine.<h4>Methods</h4>EVOLVE-1 and EVOLVE-2 were identical phase 3, randomized, double-blind, placebo-controlled studie...

Subject

Phase 3

Episodic Migraine

Galcanezumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!